Beam Therapeutics will present the first approach to highlight research into the development of non-genotoxic conditioning regimens for patients with sickle cell disease prior to autologous transplantation
Beam Therapeutics CAMBRIDGE, Massachusetts, June 27, 2022 (GLOBE NEWSWIRE) – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic drugs through base editing, today announced that new research highlighting the company’s internal efforts to develop better transplant preparation regimens for sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT) will be introduced …